We found that the number of IDO+ stromal immune cells is higher in malignant melanomas, compared with benign melanocytic lesions, and that higher amounts of IDO+ melanoma cells correlate with poor prognostic factors and poor RFS in CM. This evidence concerns the gene IDO1 and melanoma.